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ARTICLE
Non-coding variants contribute to the clinical
heterogeneity of TTR amyloidosis
Andrea Iorio1, Antonella De Lillo1, Flavio De Angelis1, Marco Di Girolamo2, Marco Luigetti3,4,5,
Mario Sabatelli6, Luca Pradotto7, Alessandro Mauro7,8, Anna Mazzeo9, Claudia Stancanelli10,
Federico Perfetto11, Sabrina Frusconi12, Filomena My13, Dario Manfellotto2, Maria Fuciarelli1 and
Renato Polimanti*,14,15
Coding mutations in TTR gene cause a rare hereditary form of systemic amyloidosis, which has a complex genotype–phenotype
correlation. We investigated the role of non-coding variants in regulating TTR gene expression and consequently amyloidosis
symptoms. We evaluated the genotype–phenotype correlation considering the clinical information of 129 Italian patients with
TTR amyloidosis. Then, we conducted a re-sequencing of TTR gene to investigate how non-coding variants affect TTR expression
and, consequently, phenotypic presentation in carriers of amyloidogenic mutations. Polygenic scores for genetically determined
TTR expression were constructed using data from our re-sequencing analysis and the GTEx (Genotype-Tissue Expression) project.
We confirmed a strong phenotypic heterogeneity across coding mutations causing TTR amyloidosis. Considering the effects of
non-coding variants on TTR expression, we identified three patient clusters with specific expression patterns associated with
certain phenotypic presentations, including late onset, autonomic neurological involvement, and gastrointestinal symptoms. This
study provides novel data regarding the role of non-coding variation and the gene expression profiles in patients affected by TTR
amyloidosis, also putting forth an approach that could be used to investigate the mechanisms at the basis of the genotype–
phenotype correlation of the disease.
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INTRODUCTION
Most of the coding variants in the transthyretin gene (TTR; OMIM
description: *176300; chromosome region 18q12.1) determine amy-
loidogenic processes, which cause TTR amyloidosis (OMIM pheno-
type description: #105210), an autosomal dominant hereditary lethal
condition.1 The pathogenesis of this disorder is driven by the
deposition of amyloid in extracellular spaces of several tissues and
organs. This scattered distribution of TTR amyloid fibrils generally
leads to a peripheral sensorimotor and autonomic neuropathy,
exhibiting variability in cardiac, gastrointestinal, renal, and ocular
involvement, as well as age of onset.2 The basis of this clinical
variability may be partially explained by the high genetic heterogeneity,
which has been linked to the existence of more than 100 amyloido-
genic mutations in TTR gene.3 Some mutations are primarily
associated with neuropathy, while others lead predominantly to
cardiomyopathy, even though both clinical displays could be featured
simultaneously to different extents.4 Moreover, although these symp-
toms may be present in patients carrying different TTR disease-causing
mutations, clinical phenotypes are not always concordant, and the
same mutation may be associated with different symptoms or signs,
even within the same family.5 A clear example of the clinical
heterogeneity of the carriers of the same TTR amyloidogenic mutation
is the Val30Met mutation (rs28933979, c.148G4A, p.(Val50Met)),
which is one of the leading causes of TTR amyloidosis.6 There are two
European Val30Met endemic foci in Portugal and Sweden, and
patients show two distinct clinical presentations. Val30Met Portuguese
families experience early onset, strong severity, and high penetrance.7
Conversely, Val30Met Swedish patients have late onset, intermediate
severity, and low penetrance.8 Moreover, high variability in penetrance
according to the gender of the transmitting parent was observed in
these geographic areas with a higher penetrance associated with
maternal transmission of the Val30Met mutation.9 In literature there
is also a case report regarding seven twin carriers of the Val30Met
mutation with discordant clinical phenotypes, and the authors
hypothesized genetic and epigenetic regulatory mechanisms as possible
explanations.10 This strongly indicates that the basis of the complex
genotype–phenotype correlation is not only due to the disease-causing
mutation, but other genetic factors could have a role in the clinical
presentation.11–14 Our previous studies have suggested the putative
impact of genetic variants located in the non-coding regions of the
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TTR gene in the modulation of the clinical phenotype of TTR
amyloidosis. First, we observed the presence of genetic variants in
binding sites for transcription factors involved in heart development in
African populations, in accordance with the manifestation of cardio-
myopathy in patients with African ancestry.15 Then, we analyzed
the haplotypes associated with the Val122Ile (rs76992529, c.424G4A,
p.(Val142Ile)) and Val30Met mutations, and identified independent
haplotypes for the same mutation, suggesting multiple mutational
events and different origins for these disease-causing mutations.16,17
As non-coding variants located in regulatory elements can affect
gene expression,18 we hypothesize that these variations influence
the distribution and accumulation of TTR-derived fibrils across
different tissues and organs, modulating consequently the disease
phenotype.
Recently, the GTEx (Genotype-Tissue Expression) project (available
at http://www.gtexportal.org/home/) has investigated the effect of
coding and non-coding variants on tissue-specific gene expression.19
These effects of genetic variants can be used to estimate the genetically
determined gene expression across human tissues, investigating its
contribution with respect to disease pathogenesis.20 This approach
permits to explore how genetic variation is associated with phenotypic
presentation through its effect on gene expression in multiple tissues.
In a recent study, we observed that genetically determined TTR
expression varies across human populations and this variation appears
to be in line with known epidemiological differences in the patients
affected.21
On this basis, we evaluated the impact of the non-coding variants
on the genetically determined TTR expression in Italian patients with
TTR amyloidosis. Indeed, we hypothesize that non-coding variation
regulating TTR gene expression in source and target tissues is one of
the mechanisms involved in the phenotypic heterogeneity observed
among the patients affected by TTR amyloidosis. However, we could
not directly test the association of the non-coding variants with respect
to every phenotypic presentation of the disease because we investigated
a rare condition (Italian prevalence: 1 in 100 000 subjects) and the
direct association analysis would have been underpowered. Conver-
sely, we used an analytic approach that allowed us to combine the
effect of non-coding variants on TTR expression across human tissues
and to test the pattern of genetically predicted TTR expression with
respect to disease symptoms.
SUBJECTS AND METHODS
Subjects
We recruited 129 symptomatic patients from six of the main Italian centers for
the diagnosis and treatment of systemic amyloidosis: IRCCS-Istituto Auxolo-
gico Italiano – Piancavallo (VB), Careggi University Hospital – Florence, ‘San
Giovanni Calibita’ Fatebenefratelli Hospital, Isola Tiberina – Rome, Fondazione
Policlinico Universitario ‘A. Gemelli’ – Rome, ‘Vito Fazzi’ Hospital – Lecce, and
Azienda Ospedaliera Universitaria Policlinico ‘G. Martino’ – Messina. The
distribution of the samples across the recruiting centers is reported in
Supplementary Table S1. This study was approved by the appropriate Bioethics
Committees. TTR amyloidosis diagnosis was based on clinical signs/symptoms,
amyloid deposits in biopsy samples, and the presence of an amyloidogenic TTR
mutation. Clinical characteristics that describe the disease phenotype (ie, age of
onset and organ involvements) were assessed as previously reported.22–26
Briefly, the following criteria were used to determine organ involvements:
peripheral neurological involvement (peripheral neuropathy); cardiac involve-
ment (electrocardiographic abnormalities); gastrointestinal involvement (gas-
tric-emptying disorder and pseudo-obstruction); autonomic neurological
involvement (orthostatic hypotension and voiding dysfunction); renal involve-
ment (altered proteinuria and renal function); ocular involvement (keratocon-
junctivitis sicca, secondary glaucoma, vitreous opacities, or pupillary
abnormalities); and impotence (self-reported). Of the 129 patients, 55 agreed
to provide the biological sample needed to conduct a re-sequencing analysis of
their TTR gene, including coding and non-coding regions. As no criteria was
applied to select the samples to be investigated in the sequencing analysis
(except for the availability of the biological specimen needed for the DNA
extraction), no selection bias is expected.
Genetic analysis
DNA, extracted through the standard phenol/chloroform technique, was
checked by the quality control and its quantification. The quality control was
carried out by spectrophotometry (Varian Cary 50 Bio UV/Visible Spectro-
photometer, Varian Medical Systems, Palo Alto, CA, USA), while the
quantification was carried out by Real Time-PCR (Quantifiler Duo DNA
Quantification Kit, Applied Biosystems, Foster City, CA, USA). The TTR gene
structure was analyzed through double-strand Sanger sequencing (3500 Genetic
Analyzer). A 20 kb region (GRCh37 chromosome 18:29,164 000–29 185 000)
was re-sequenced, including the TTR gene (7257 bp), ~ 6000 bp upstream (5′-
UTR) and ~6000 bp downstream (3′-UTR) regions. Forty-five overlapping
segments were amplified and sequenced using the same protocol reported in a
previous study by Soares et al.27
Sequencing data analysis
We used Geneious v.9.1.5 software (http://www.geneious.com/ Biomatters Ltd.,
Auckland, New Zealand) to reconstruct the entire 20 kb region for each of the
55 patients. First, we checked the chromatograms by using the quality control
and the trimming tools available through the software. Afterwards, we mapped
the forward and reverse sequenced tracts with a reference sequence obtained
from the 1000 Genomes database (GRCh37 chr18:29164000–29185000). To
annotate the variants, we considered the following transcript and protein
reference sequences: NM_000371.3 and NP_000362.1. The variant calling was
performed with the Geneious v.9.1.5 software. The 53 identified variants
(excluding the amyloidogenic mutations) were annotated by HaploReg v.4.1.28
The sequencing results were deposited in the Leiden Open Variation Database
available at www.lovd.nl/TTR (Individual ID from 00103269 to 00103323).
Genetically determined TTR gene expression estimation
The GTEx Version 6 data (available at http://www.gtexportal.org/home/) were
used as reference data sets for genetically determined gene expression. We
extracted the comprehensive information (effect size and P-value) pertinent to
26 variants and 46 tissues (Supplementary Table S2). We then performed a
linkage disequilibrium (LD) clumping analysis (P= 1; r2= 0.8; region
size= 10 kb) using Plink 1.0729 to obtain 46 tissue-specific data sets accounting
for LD structure (Supplementary Table S3). All data sets consisted of genetic
variants in non-coding regions of the TTR gene, with the exception of the
missense not-pathological rs1800458. We used these tissue-specific clumped
data sets to calculate the individual polygenic scores for the genetically
determined TTR expression, on the basis of effect allele count and allele effect
size, using Plink 1.07. Specifically, for each tissue the scores were calculated
weighting the allele dosage by its effect on TTR expression in the corresponding
tissue.
Statistical analysis
The initial analysis was conducted on the phenotypic information available
for the 129 symptomatic patients. A hierarchical clustering analysis, using
the Jaccard method for binary variables, was conducted to correlate the
amyloidogenic mutation and the clinical information. This analysis was
performed using ‘arules’ R package30 and the cluster significance using
‘pvclust’ R package (available at https://cran.r-project.org/web/packages/
pvclust/index.html) by applying 100 000 bootstrap replications. We con-
sidered clusters with an approximately unbiased P-value 495% as
significant.
The second phase of the study was to investigate the relationship between
coding and non-coding TTR variation and clinical characteristics of the 55
sequenced patients. The haplotype reconstruction (for all the identified
variants and amyloidogenic mutations) was conducted using PHASE 2.131
and the haplotype association with clinical phenotypes was performed with
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Haploview 4.2.32 We performed a hierarchical clustering analysis on the
polygenic scores using MeV 4.8.1 software (available at http://www.tm4.org/
mev.html) and calculated the cluster significance using ‘pvclust’ R package as
described above. We generated a distance metric using the Spearman rank
correlation method, and the clustering was conducted using the average linkage
method. For the significant clusters, we checked the statistical significance of
the clinical phenotypes by comparing their observed frequencies with the null
distribution generated through 10 000 random permutations of the phenotypic
data with respect to polygenic scores.
RESULTS
The characteristics related to the amyloidogenic mutations and clinical
phenotypes of the 129 Italian patients are shown in Table 1. The most
frequent mutation is Val30Met (N= 55), followed by Phe64Leu
(rs121918091, c.250T4C, p.(Phe84Leu); N= 28), Glu89Gln
(rs121918082, c.325G4C, p.(Glu109Gln); N= 28), Thr49Ala
(rs121918081, c.205A4G, p.(Thr69Ala); N= 7), Ala120Ser
(rs876658108, c.418G4T, p.(Ala140Ser); N= 3), Ile68Leu
(rs121918085, c.262A4T, p.(Ile88Leu); N= 3), Val122Ile (N= 3),
Ala109Ser (rs267607159, c.385G4A, p.(Ala129Thr); N= 1), and
Thr59Lys (rs730881163, c.236C4A, p.(Thr79Lys); N= 1). We
observed similar symptom patterns across patients with different
amyloidogenic mutations with few exceptions (Figure 1). Cardiac,
autonomic neurological, peripheral neurological, and gastrointestinal
symptoms were observed in most of the amyloidogenic mutations.
However, we observed few strong correlations between amyloidogenic
mutations and some phenotypic traits. Ocular symptoms were only
observed in Val30Met patients. Ile68Leu and Val122Ile patients almost
exclusively showed the cardiac phenotype. Applying hierarchical
clustering (Figure 2), we observed significant correlation between
the Val30Met mutation and ocular symptoms (approximately
unbiased P495%) and between the Phe64Leu mutation and renal
involvement (approximately unbiased P495%). Both the Ile68Leu
and Val122Ile mutations were significantly associated with the cardiac
symptoms (approximately unbiased P495%).
Re-sequencing coding and non-coding regions of the TTR gene in
55 patients, we identified 53 variants (Supplementary Table S4),
including 43 SNPs and 10 INDELs (21 in the upstream region, 8 in
introns, 1 in the coding regions, and 24 in the downstream region).
Four of the 53 variants (NC_000018.9:g.29164968C4T,
g.29179948G4A, g.29182334A4G, and g.29182576T4C) are novel
and not annotated in the international reference databases and
genome browsers (dbSNP, 1000 Genomes, UCSC Genome Browser,
Ensembl). Functional annotation analysis (Figure 3) indicated that 9
variants are associated with regulatory elements in the promoter
region, 31 are associated with regulatory elements in the enhancer
regions, 20 are found in DNAse-sensitive loci, 5 are located in protein-
binding sites, 39 alter transcription factor-binding sites, and 5 are
known expression quantitative trait loci.
We performed the haplotype inference considering the 53 identified
variants and the 7 amyloidogenic mutations. The haplotypes associated
with the disease-causing mutations of the 55 patients are reported in
Supplementary Table S5. Through the haplotype association analysis,
we found a specific Val30Met haplotype significantly associated with
ocular symptoms (P= 8× 10− 4). This Val30Met haplotype contains
two regulatory variants: rs5823817 and rs58272364. These variants are
intronic and are associated with regulatory elements in enhancer
regions. Furthermore, rs5823817 is also located in in a DNAse-
sensitive locus.
As explained in Subjects and Methods, we used our sequencing
data to estimate genetically determined TTR expression across
human tissues. We applied a hierarchical clustering analysis to
these data to identify subjects with similar TTR expression
(Figure 4). We identified five significant patient clusters (approxi-
mately unbiased P495%), which include patients with different
amyloidogenic mutations: cluster 1 (Val30Met, Phe64Leu, and
Ile68Leu); cluster 2 (Val30Met and Glu89Gln); cluster 3 (Phe64Leu


















Val30Met 55 14 (25) 27 (49) 39 (71) 55 (100) 22 (40) 8 (15) 16 (29) 20 (49)
Phe64Leu 28 6 (21) 19 (68) 24 (86) 25 (89) 19 (68) 6 (2) 0 (0) 19 (86)
Glu89Gln 28 17 (61) 24 (86) 23 (82) 27 (96) 19 (68) 1 (4) 0 (0) 11 (100)
Thr49Ala 7 3 (43) 6 (86) 7 (100) 7 (100) 6 (86) 1 (14) 0 (0) 3 (100)
Ala120Ser 3 3 (100) 2 (67) 2 (67) 3 (100) 2 (67) 0 (0) 0 (0) 0 (0)
Ile68Leu 3 0 (0) 3 (100) 0 (0) 1 (33) 0 (0) 0 (0) 0 (0) 0 (0)
Val122Ile 3 0 (0) 3 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Ala109Ser 1 0 (0) 1 (100) 1 (100) 1 (100) 1 (100) 0 (0) 0 (0) 1 (100)
Thr59Lys 1 0 (0) 1 (100) 1 (100) 1 (100) 1 (100) 0 (0) 0 (0) 1 (100)
Abbreviations: ANS, autonomic nervous system involvement; Gastro/Int., gastrointestinal; PNS, peripheral nervous system involvement.
aImpotence is assessed in men only.
Figure 1 Radar diagram of symptoms across amyloidogenic mutations. The
percentages are calculated with respect to the total number of organ
involvements reported for each TTR mutation. The full colour version of this
figure is available at European Journal of Human Genetics online.
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and Val122Ile); cluster 4 (Ala120Ser and Phe64Leu); and cluster 5
(Val30Met and Phe64Leu). We performed a permutation analysis
to verify whether the patients included in the clusters identified on
the basis of the genetically predicted TTR expression are associated
with specific symptoms. Clusters 3 and 4 were excluded from
further analysis because of their small sample size (N= 3). Subjects
included in cluster 1 showed a higher age of onset and a lower
prevalence of autonomic neurological symptoms than those
expected by chance (ppermutation= 0.013 and 0.035, respectively;
Supplementary Figure S1). An increased prevalence of autonomic
neurological symptoms (trend significance; ppermutation= 0.087) was
observed in the subjects included in cluster 2 (Supplementary
Figure S2). In cluster 5, we observed subjects with a higher
prevalence of gastrointestinal phenotype than that expected by
chance (ppermutation= 0.047; Supplementary Figure S3).
DISCUSSION
Our findings provided novel insights into the molecular mechanisms
at the basis of the genotype–phenotype correlation of TTR amyloi-
dosis. Considering the clinical information available for the 129 Italian
patients investigated in the present study, we confirmed a strong
phenotypic heterogeneity: the main symptoms (neurological, cardiac,
and gastrointestinal) were observed across different amyloidogenic
mutations. This indicates that the symptom pattern in TTR amyloi-
dosis is not exclusively determined by the disease-causing mutation
but other mechanisms should be involved. However, we also observed
few strong genotype–phenotype correlations: Val30Met mutation with
the ocular involvement; and Val122Ile and Ile68Leu mutations with
the cardiac phenotype. These phenotype–genotype correlations are
supported by previous studies. The ocular involvement in patients
with TTR amyloidosis is generally a rare manifestation33 because it
depends on numerous factors (eg, liver transplantation, disease age of
onset, and disease duration), but it is well described in several studies
of Val30Met TTR amyloidosis in Portuguese families.34,35 The
Val122Ile mutation is widely described in the literature as the leading
cause of cardiac amyloidosis in patients with African ancestry.36 This
correlation was also confirmed in patients of European descent.25,37
The Ile68Leu mutation was previously described in Italian patients
with cardiac or mixed neurological/cardiac phenotypes.4,25
The re-sequencing analysis of the TTR gene (coding and non-
coding regions) in Italian patients allowed us to deepen our previous
finding on the role of non-coding TTR variations in the disease
genotype–phenotype correlation.15–17 Investigating the TTR haplotypic
structure, we observed that the correlation between the Val30Met
Figure 2 Hierarchical clustering based on clinical symptoms and amyloidogenic mutation reported in the 129 patients with TTR amyloidosis. Red boxes
highlight the significant clusters (approximately unbiased (AU) P495%; bootstrap probability (BP)). Gastr.Int, gastrointestinal involvement; SNA, autonomic
neurological involvement; SNP, peripheral neurological involvement. The full colour version of this figure is available at European Journal of Human
Genetics online.
Figure 3 Functional annotation of the variants identified by TTR gene re-
sequencing.
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mutation and the ocular manifestation can be attributed to a specific
Val30Met haplotype, which includes two regulatory non-coding
variants. As also reported in genetic studies of different phenotypic
traits,38,39 the ocular manifestation in TTR amylodosis in our sample is
due to a combination of the effects of a coding amylodogenic
mutation and SNPs located in non-coding elements.
Using of the data from the GTEx consortium,19 we leveraged our
sequencing data to calculate the genetically predicted expression
profiles of the TTR gene across 46 human tissues. These expression
profiles reflect the patterns of TTR expression influenced by the
genetic control. Consequently, they should be related to potential
pathogenic mechanisms linked to TTR expression across human
tissues and not to the consequences of the disease progression.
Considering these expression profiles, we identified three patient
clusters with specific expression patterns that were associated with
particular phenotypic presentations: cluster 1, late onset and low
prevalence of autonomic neurological involvement; cluster 2, high
prevalence of autonomic neurological involvement; and cluster 5, high
prevalence of gastrointestinal symptoms. This indicates that the
genetic variation involved in the regulation of TTR expression across
human tissues is one of the mechanisms responsible for the clinical
presentations observed in the carriers of TTR amyloidogenic muta-
tions. Furthermore, the effects of non-coding regulatory elements
appear independent of the amyloidogenic mutations: variants involved
in TTR gene expression regulation are involved in the disease
manifestation with similar effects across different disease-causing
mutations.
Owing to the limited availability of tissue samples taken from
affected patients, mechanisms related to gene expression in TTR
amyloidosis have been poorly investigated. Recently, an in vitro study
demonstrated that Schwann cells can contribute to neurodegeneration
through the local expression of mutated TTR.40 TTR gene expression
patterns across different tissues, including source and target organs,
could contribute to the symptoms observed in patients, which is in
agreement with our current findings.
In conclusion, the present study provided novel data regarding the
role of non-coding variation and the expression profiles of TTR gene
in affected patients, also introducing an innovative approach to
investigate the mechanisms at the basis of disease symptoms. Further
experimental studies are needed to confirm our results. Furthermore,
other mechanisms (eg, epigenetics and modifier genes) can also
contribute to the disease genotype–phenotype correlation, and local
gene expression profile may reflect one of the molecular processes that
contribute to the genotype–phenotype correlation of TTR amyloidosis.
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